Treatment of minimal residual disease positive acute myeloid leukemia patients

01 January 2015 → 31 December 2018
Funding by bilateral agreement (private and foundations)
Research disciplines
  • Medical and health sciences
    • Immunology
    • Immunology
    • Immunology
acute myeloid leukemia
Project description

Chemotherapy leads to cure of acute myeloid leukemia (AML) lead to cure in

less than half of the patients. Stem cell transplantation can be used as an

immunotherapeutic treatment to cure the patient, but carries a high risk of

toxicity and mortality, especially older patients with comorbidities. Moreover,

not all patients have a suitable donor.

We have developed a novel immunotherapeutic treatment, in which we

generate in vitro, starting from mobilized hematopoietic precursor cells, Tcells

that recognize WT1, a tumor antigen that is overexpressed on 70% of

the AMLs. In this project, we will translate our research protocol into a clinical

grade protocol to generate WT1-specific T-cells from patients: the protocol

will be optimized on chemotherapy treated left-over patient mHPC; cell

isolation procedures and cell cultures will be adapted to good manufacturing

practices in our GMP-facility and proper quality control tests will be set up.